VC fund profile · evidence-aware directory data

F-Prime Capital stages, portfolio and investment profile

Cambridge-based venture firm affiliated with Fidelity Investments, with a heritage tracing to Fidelity's venture arm. Self-capitalized investor in life sciences, healthtech, enterprise software, fintech, and frontier technology across North America and Europe.

Keep track of F-Prime Capital

Save this profile to your VCT watchlist for a quick return.

View watchlist

Stage-based planning range

$1M–$10M

This is a planning range inferred from stage coverage, not a firm-disclosed check size.

Methodology: Stage bucket inferred from the rounds a fund leads or invests in.

No firm-specific check-size disclosure is recorded.

Source link not recorded Confidence: 25% Verified: Not recorded View methodology

Investment stages

Leads: Series A, Series B+

Participates: Seed, Series A, Series B+

Sector focus

Healthtech · Biotech & Life Sciences

Geography

Cambridge, MA

Founded 2016

Fund size / AUM

Not recorded

A separate fund-size evidence record is not yet available.

Portfolio in our directory

Linked startup profiles

Latest fund vehicle

Not recorded

Vehicle name, size, and vintage are not yet structured.

Recent tracked investment

Nava Therapeutics

Series A · $89M · 2024

Rounds they lead

Series A Series B+

Rounds they invest

Seed Series A Series B+

Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.

Portfolio companies we track

Startups in our directory that list F-Prime Capital as an investor (6 total).

FAQs about F-Prime Capital

Stage fit, check size, thesis, and how founders typically approach this firm — based on public sources and our directory.

Per our directory, F-Prime Capital leads Series A and later rounds and participates from seed onward. The firm is early-stage by preference but publicly describes itself as stage-agnostic for exceptional teams.

F-Prime does not publish one fixed check. Its website cites $5.3B+ under management with capacity from seed through growth; third-party profiles and the firm's own materials describe wide flexibility by stage rather than a single standard ticket.

F-Prime Capital is headquartered in Cambridge, Massachusetts, with offices in London and San Francisco. It invests across the Americas and Europe in healthcare and technology.

Our directory tags healthtech and biotech-life-sciences. F-Prime publicly invests in life sciences (therapeutics, medtech), healthtech services, enterprise software, fintech, frontier tech, and crypto—often favoring clear regulatory pathways in healthcare.

F-Prime frequently leads or co-leads seed and Series A rounds, especially in healthcare and technology, and participates in later follow-ons for portfolio winners given its self-capitalized structure.

Startups in our directory with F-Prime Capital listed include Firefly Health (/startup/firefly-health), Zus Health (/startup/zus-health), PatientPing (/startup/patientping), BioAge Labs (/startup/bioage-labs), and Nava Therapeutics (/startup/nava-therapeutics).

Founders can reach the team through fprimecapital.com. Warm intros from scientists, clinicians, or prior portfolio founders help in healthcare; we do not list individual partner inboxes.

We do not yet have a dedicated F-Prime fund article. Our digital-health and biotech industry hubs reference healthcare investors active in overlapping sectors.

Website

By Venture Capital Tracker

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.